Syngene International Limited | LinkedIn (original) (raw)

About us

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 6000 scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com or write to us at bdc@syngeneintl.com

Industry

Research Services

Company size

5,001-10,000 employees

Headquarters

Bengaluru, Karnataka

Type

Public Company

Founded

1993

Specialties

Drug Discovery, Drug Development, Drug Manufacturing, Small Molecules, Biologics, Integrated Drug Discovery, Peptides, Oligonucleotides, Antibody Drug Conjugates, PROTACs, Rare and Orphan Drugs, CAR-T, pDNA & mRNA, Central Compound Management, Discovery Chemistry, Discovery Biology, Safety Assessment, Computational & Data Sciences, Chemical Development, Formulation Development, Clinical Development, Analytical Development, Commercial Manufacturing, Sterile Fill-Finish, Molecular Biology, Protein Sciences, Cell Line Development & Analysis, Antibody Generation, Analytical Characterization & Quality Control, Viral Testing & Clearance, Bioanalytical Laboratory Services, and Mammalian Gene to GMP

Locations

Employees at Syngene International Limited

Updates

510,009 followers
1w Edited
Introducing our first session in the DMPK Unravelled webinar series! Join us for an in-depth look at ADME strategy and challenges tailored for heterobifunctional degraders. 📅 Date: December 4, 2024 🕙 Time: 10:00 am EST / 7:30 pm IST This session will explore the complexities of Targeted Protein Degradation (TPD) and overcoming ADME challenges associated with large degrader molecules. Our keynote speaker for the first webinar, Prasoon Chaturvedi, Vice President, Head of DMPK at C4 Therapeutics, Inc., will discuss the application of strategic DMPK screening to support the development of effective and orally bioavailable protein degraders, while our in-house speakers - Vishwottam Kandikere and Amol Raje, will discuss some case studies on the same. Register now #DMPK #DMPKUnravelled #Syngene #DrugDiscovery
This content isn’t available here
Access this content and more in the LinkedIn app
📌We are excited to attend the ACT 2024 Annual Meeting at Austin, Texas from November 17 to 20, 2024. Meet our experts to discuss how Syngene can help you accelerate your drug discovery programs. To book a meeting, visit the link in the comments section. We offer a full range of exploratory and good laboratory practice (GLP) toxicology services that enable clients to assess the safety profile of new drugs (NMEs), agrochemicals, vaccines, cosmetics, and food additives. Our capabilities include - ⦿ Full range of toxicology services including in silico, in vitro, genotox, rodent, and non-rodent studies. Over 750 in-vitro and 500+ in-vivo tox studies have been completed in the last five years and submitted to global regulatory agencies successfully. ⦿ 13+ comprehensive IND-enabling tox packages delivered in the last 5 years for US, European and Japanese clients. ⦿ Experience with biocompatibility testing (ISO 10993) testing of medical devices in ISO/IEC-17025 (NABL, India) and GLP-accredited facilities. ⦿ Analytical and Bioanalytical support under GLP environment. ⦿ OECD and ICH guidelines-compliant clinical pathology and histopathology services ⦿ In-house SEND capabilities are fully compliant with US-FDA requirements. ⦿ Team of 65+ people, including 9 DABTs, 3 ERTs, and four board-certified veterinary pathologists, to support your projects within the best turnaround timelines.#SyngeneDiscovery #ACTmeeting2024 #Toxicology #SafetyAssesment
We’re excited to attend Biofit 2024 in Lille, France, from December 3rd to 4th, 2024. Visit us at booth #B-36 to meet our experts and discover how Syngene can support your journey from discovery through development to market. With over 6,000 scientists and industry experts, Syngene has the expertise and capacity to deliver excellent science, robust data management, IP security, and high-quality manufacturing. We partner with early-stage companies, start-ups, and Big Pharma to accelerate time-to-market and reduce the cost of innovation across the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. To book a meeting, visit the link in the comments section. #DrugDiscovery#CRDMO #Biofit2024
510,009 followers
3d Edited
Bile-iant Innovation: Cholestatic Disease Treatment A prominent biotech company collaborated with Syngene to develop a first-in-class inhibitor targeting cholestatic diseases. Through cutting-edge medicinal chemistry and rigorous profiling, our team identified a potent molecule that reduces bile acid concentration, marking significant progress in treating this condition. The novel drug is now advancing to preclinical development, showcasing the power of strategic partnerships in accelerating drug discovery and development. Read the full case study 👉 https://lnkd.in/gdVHsC5i #NASH #Noveldrug #DMPK #ADME
We're excited to share that Syngene recently participated in an engaging panel discussion on opportunities in the pharma domain at M. S. RAMAIAH UNIVERSITY OF APPLIED SCIENCES. Gladson Vinod and Nainesh Kumar Dwivedi represented Syngene in this discussion. We extend our heartfelt thanks to the students and faculty for their enthusiasm and keen interest. Your curiosity and passion for learning were truly inspiring. At Syngene, we believe that such interactions are invaluable in fostering industry-academia relationships and nurturing the next generation of innovators. Thanks to everyone involved for making this discussion a success Prabhakar Jaiswal | Jaideep K | Shibin Balan
Syngene International Limited reposted this

13,553 followers
6d Edited
Every Tuesday, we gather for inspiring insights and meaningful connections over breakfast. Today, we had the pleasure of hosting Lucia Babes, who shared Syngene International Limited's approach to drug discovery. Through their integrated expertise in biology, chemistry, and ADMET, Syngene is driving faster, smoother transitions of molecules from lab to clinic. Read more about our upcoming events via the link in the comments below.#sciencepark #syngeneinternational
510,009 followers
6d Edited
We are hiring! We are conducting Walk-in interviews at Ahmedabad on 16th November (Saturday) for multiple openings in the Discovery Biology group for DMPK (Drug Metabolism & Pharmacokinetics) department. If you wish to be part of a dynamic, high-performing team for bringing new solutions to drug discovery and changing people's lives for the better, please read more. We seek highly motivated, creative, and results-oriented scientists with multiple positions open at Hyderabad, who have relevant experience in invitro drug metabolism assay, and LCMS-based discovery bioanalysis. The candidate should have an excellent understanding of the fundamentals of drug metabolism and pharmacokinetics principles and drug discovery; prior experience in progressing a project from hit identification to lead optimization is a plus. Qualification and Experience: · MSc/MTech/M. Pharm: Candidates should have 2 to 10 years of relevant experience (Freshers are not eligible for the current roles). · PhD: Only candidates with experience in Invitro ADME are eligible. Details as below: 1. Req Id: 58099 - Bioanalytical Scientist Click 👉 https://lnkd.in/gsur8t6G2. Req Id: 58116 – Invitro ADME Scientist Click 👉 https://lnkd.in/gQQ_f3H53. Req Id: 58184 – Invivo PK Click 👉 https://lnkd.in/gHvRw4kBJob Location: Bangalore and Hyderabad Date & Time for Registration: 16th November, 09:00 AM to 12.30 PM Venue: Lemon Tree Premier, The Atrium, Ahmedabad, Off Nehru Bridge, Sabarmati River Front, Ahmedabad, Gujarat - 380001, India Please apply on the above links and write to 👉 abhisek.padhy@syngeneintl.com with the subject line “Syngene DMPK Walk-in Drive” for more details.#WeareHiring #WalkinDrive #Syngene
510,009 followers
6d Edited
📌Accelerating Biologics Development through Advanced Biophysical Analysis. Biophysics and biochemistry play a pivotal role in deciphering critical quality attributes (CQAs) to ensure consistent manufacturing processes. Advanced biophysical techniques accurately characterize higher-order structures and CQAs, determining product quality, safety, and efficacy. This streamlines regulatory approvals and accelerates time-to-market for biotechnology companies. Stringent quality checks across the drug discovery-development continuum ensure all deliverables meet the highest standards. Explore how Biophysics-powered tools are crucial for accurately identifying Critical Quality Attributes (CQAs) in biologics. Read viewpoint, https://lnkd.in/gGdP5c-W 🔗#Biophysics #Biologics #RegulatoryScience #CMC

Join now to see what you are missing

Join now

Syngene International Limited | LinkedIn (original) (raw)

About us

Locations

Employees at Syngene International Limited

Updates

Join now to see what you are missing

Similar pages

Browse jobs

Funding